Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments

The commenter advocates for the approval and release of a specific treatment (Anktiva/ImmunityBio Inc.) to treat conditions like lymphopenia and sepsis. They argue that the treatment is safe and effective and should be made available to the thousands of people currently waiting for it.

The commenter is an individual demanding the approval of ANKTIVA to save lives and improve the U.S. biosector. They argue that the agency is prioritizing pharmaceutical profits over patient needs and call for faster regulatory action.

An individual patient or family member advocates for the approval of Anktiva for the treatment of Glioblastoma. They argue that the disease is rapidly progressive and devastating, emphasizing the urgent need for treatment options for patients with limited hope.

Mohammad Zaman, PhD, argues that ANKTIVA and related ImmunityBio immunotherapy programs should be prioritized under the Commissioner’s National Priority Voucher Pilot Program due to their ability to address significant unmet medical needs in various cancers. He highlights the drug's innovative IL-15 mechanism, its existing FDA approval, and the potential for substantial public health benefits and improved patient outcomes.